How a new pill could reduce asthma attacks
The drug Fevipiprant improves air flow to the lungs by removing muscle in the airway lining, a study has shown
![A variety of pills and drugs](https://cdn.mos.cms.futurecdn.net/8bzWpxX2Tn3LTnmyuP5vqJ-415-80.jpg)
Scientists from the University of Leicester have successfully trialled a new pill that reduces asthma attacks by targeting airway muscles.
The experimental drug Fevipiprant “is the first oral treatment for asthma in 20 years”, says the Press Association.
The new study shows that the drug works by reducing the amount of muscle in the airway lining. Previous trials had shown that it improves breathing, reduces inflammation and helps to repair the lining of patients’ airways but the new study is the first to show exactly how it does it.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
![https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516-320-80.jpg)
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Professor Chris Brightling, from the University of Leicester, said: “Our research shows for the first time that Fevipiprant not only reduces inflammation in the airways, but also reduces the amount of muscle in the lining of the airway. This is likely to explain some of the effects seen in the symptoms and breathing tests following treatment.”
He added: “Our findings suggest that Fevipiprant could have positive long-term effects upon the progression of the disease through remodelling, as well as improve symptoms and reduce attacks.”
The asthma drug “specifically blocks the activation of a muscle protein, which reduces the movement of the immature muscle cells from forming a bundle and blocking the airway”, says Sky News.
There are more than 300 million people who are affected by asthma worldwide and the number is increasing. In the UK there are roughly around 500,000 people who have moderate to severe forms of asthma.
Currently “there are no drugs available on the NHS which treat the build-up of smooth muscle mass as a method of reducing asthma symptoms”, adds Sky News.
For people with severe asthma, “a procedure called thermoplasty, which uses thermal energy to decrease the amount of smooth muscle in the airways, may be offered”, says Medical Xpress. This requires “sedation in hospital and is not a cure, nor suitable for everyone”, the website adds.
Most people in the UK affected by asthma are able to routinely manage the condition with inhaled drugs and steroids.
But Fevipiprant could offer sufferers a way to avoid some of the side-effects associated with using steroids including weight gain.
Dr Himanshu Kaul, a postdoctoral fellow in the School of Biomedical Engineering at the University of British Columbia who helped with the trial, said: "Our computer model represents a milestone towards patient-specific models in respiratory medicine that has the potential to help design new drugs and optimise existing therapies."
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Netanyahu makes controversial address
Speed Reads Israeli Prime Minister Benjamin Netanyahu's speech to Congress denounced Gaza war protestors
By Rafi Schwartz, The Week US Published
-
Twisters review: 'warm-blooded' film explores dangerous weather
The Week Recommends The film, focusing on 'tornado wranglers', stars Daisy Edgar-Jones and Glen Powell
By The Week UK Published
-
The US presidents who decided not to run for a second term
The Explainer Joe Biden's decision to end his re-election campaign was shocking, but there's a long history of presidents who've bowed out on a chance at four more years
By Rafi Schwartz, The Week US Published
-
Mushroom edibles are tripping up users
the explainer The psychedelics can sometimes have questionable components
By Devika Rao, The Week US Published
-
Rapamycin: the popular drug for longevity among biohackers
Under the Radar Living longer may be getting easier
By Devika Rao, The Week US Published
-
Pharmaceutical companies are warning of a rise in knockoff drugs
Under the Radar The World Health Organization is also urging consumers to be cautious
By Justin Klawans, The Week US Published
-
FDA panel rejects ecstasy to treat PTSD
Speed Read It cited flawed study data and the potential for abuse
By Peter Weber, The Week US Published
-
The push to ban decaf coffee
Under the radar Going caffeine-free can be risky
By Devika Rao, The Week US Published
-
US overdose deaths fell in 2023, still topped 100k
Speed Read New CDC data shows drug overdose deaths dropped for the first time in five years
By Peter Weber, The Week US Published
-
What reclassifying cannabis could change
The Explainer The Biden administration's move to change marijuana from a Schedule I narcotic to Schedule III could reshape the pot landscape even if it doesn't mean full federal legalization
By Rafi Schwartz, The Week US Published
-
Narcan is becoming harder to find at drugstores across America
Under the Radar The drug, also known as naloxone, reverses the effects of an opioid overdose
By Justin Klawans, The Week US Published